Anti-Melphalan-modified DNA [MP5/73]

Gould et al. 2004. Mol Pharmacol. 66(5):1301-9. PMID: 15308759.

p53 elevation in relation to levels and cytotoxicity of mono- and biFn melphalan-DNA adducts.

Rothbarth et al. 2004. Biochem Pharmacol. 67(9):1771-8. PMID: 15081876.

Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo.

Frank et al. 2003. Exp Cell Res. 283(2):127-34. PMID: 12581733.

Quantification of DNA adducts in individual cells by immunofluorescence: effects of variation in DNA conformation.

McCartney et al. 2001. Chem Res Toxicol. 14(1):71-81. PMID: 11170510.

Antibody recognition of melphalan adducts characterized using immobilized DNA: enhanced alkylation of G-Rich regions in cells compared to in vitro.

Tilby et al. 1998. Chem Res Toxicol. 11(10):1162-8. PMID: 9778312.

A monoFn derivative of melphalan: preparation, DNA alkylation products, and determination of the specificity of monoclonal antibodies that recognize melphalan-DNA adducts.

Frank et al. 1996. Blood. 88(3):977-84. PMID: 8704257.

Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells.

Tilby et al. 1993. Eur J Cancer. 29A(5):681-6. PMID: 8471325.

Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy.

Tilby et al. 1990. Chem Biol Interact. 73(2-3):183-94. PMID: 2155711.

Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products from reaction of melphalan with dGMP and GMP.

Tilby et al. 1987. Cancer Res. 47(6):1542-6. PMID: 3815354.

Immunological detection of DNA damage caused by melphalan using monoclonal antibodies.